Pharmacologic management of Raynaud's phenomenon.
Raynaud's phenomenon (RP) represents a wide spectrum of disease activity. Specific pharmacologic therapy, when indicated, should be based upon the clinician's understanding of drug effectiveness and side effects. We present an update of currently available pharmacologic agents being used for RP and review the effectiveness and side effects of these drugs.
D001792:Blood Platelets / Q000187:drug effects; D001809:Blood Viscosity / Q000187:drug effects; D005340:Fibrinogen / Q000032:analysis; D006118:Griseofulvin / Q000627:therapeutic use; D006801:Humans; D008750:Methyldopa / Q000627:therapeutic use; D009543:Nifedipine / Q000627:therapeutic use; D010276:Parasympatholytics / Q000627:therapeutic use; D010643:Phenoxybenzamine / Q000627:therapeutic use; D011928:Raynaud Disease / Q000188:drug therapy*; D011941:Receptors, Adrenergic / Q000187:drug effects; D012110:Reserpine / Q000627:therapeutic use
D010276:Parasympatholytics; D011941:Receptors, Adrenergic; D010643:Phenoxybenzamine; D006118:Griseofulvin; D008750:Methyldopa; D012110:Reserpine; D005340:Fibrinogen; D009543:Nifedipine